OTR Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $104.77M |
|---|---|
| IPO Date | Nov 17, 2020 |
| CEO | Nicholas J. Singer |
| Left Lead | Maxim |
| IPO Cash in Trust | 102.2% |
| SPAC Tenor | 18 months |
| IPO Sector |
General
Not specified |
| IPO Geography | Global |
| Target Company | Comera Life Sciences |
| Deal Announced | Jan 31, 2022 |
| Deal Size, $M | $151.30M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | May 10, 2022 |
| Amendment Vote | TBD |
| Closing Date | May 19, 2022 |
Formerly OTRA
CMRA
CMRAW
| Price | $0.00 |
|---|---|
| Last closing price | $0.00 |
| H/L, 52-week | $0.22 / $2.17 |
| Volume, today | 122,889 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on OTR Acquisition Corp.:
- Structure and cap table
- 6 directors & officers
- 25 filings and events
- 2 underwriters
- 1 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Nicholas J. Singer | 41 | CEO and Chairman |
| Douglas B. Anderson | 51 | CFO and Director |
| David Neithardt | 51 | Director |
| Glenn Gray | 66 | Director |
| Nadav Besner | 41 | Director |
| Mr. Amir Rozwadoski | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Maxim | BR | 8,052,500 | units |
| EarlyBirdCapital | 1,947,500 | ||
| 10,000,000 | units | ||
| Up-Front UW fee | 1.25 | % | |
| Deferred UW fee |
3.24 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.